Cargando…
Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
PURPOSE: The utility of real-world data (RWD) for use as external controls in drug development is informed by studies that replicate trial control arms for different endpoints. The purpose of this study was to replicate control arms from four non–small cell lung cancer (NSCLC) randomized controlled...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355621/ https://www.ncbi.nlm.nih.gov/pubmed/35511917 http://dx.doi.org/10.1158/1078-0432.CCR-22-0471 |
_version_ | 1784763336471085056 |
---|---|
author | Ton, Thanh G.N. Pal, Navdeep Trinh, Huong Mahrus, Sami Bretscher, Michael T. Machado, Robson J.M. Sadetsky, Natalia Chaudhary, Nayan Lu, Michael W. Riely, Gregory J. |
author_facet | Ton, Thanh G.N. Pal, Navdeep Trinh, Huong Mahrus, Sami Bretscher, Michael T. Machado, Robson J.M. Sadetsky, Natalia Chaudhary, Nayan Lu, Michael W. Riely, Gregory J. |
author_sort | Ton, Thanh G.N. |
collection | PubMed |
description | PURPOSE: The utility of real-world data (RWD) for use as external controls in drug development is informed by studies that replicate trial control arms for different endpoints. The purpose of this study was to replicate control arms from four non–small cell lung cancer (NSCLC) randomized controlled trials (RCT) to analyze overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) using RWD. PATIENTS AND METHODS: This study used RWD from a nationwide de-identified database and a clinico-genomic database to replicate OS, PFS, and ORR endpoints in the chemotherapy control arms of four first-line NSCLC RCTs evaluating atezolizumab [IMpower150–wild-type (WT), IMpower130-WT, IMpower131, and IMpower132]. Additional objectives were to develop a definition of real-world PFS (rwPFS) and to evaluate the real-world response rate (rwRR) endpoint. RESULTS: Baseline demographic and clinical characteristics were balanced after application of propensity score weighting methods. For rwPFS and OS, RWD external controls were generally similar to their RCT control counterparts. Across all four trials, the hazard ratio (HR) point estimates comparing trial controls with external controls were closer to 1.0 for the PFS endpoint than for the OS endpoint. An exploratory assessment of rwRR in RWD revealed a slight but nonsignificant overestimation of RCT ORR, which was unconfounded by baseline characteristics. CONCLUSIONS: RWD can be used to reasonably replicate the OS and PFS of chemotherapy control arms of first-line NSCLC RCTs. Additional studies can provide greater insight into the utility of RWD in drug development. |
format | Online Article Text |
id | pubmed-9355621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-93556212023-01-05 Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data Ton, Thanh G.N. Pal, Navdeep Trinh, Huong Mahrus, Sami Bretscher, Michael T. Machado, Robson J.M. Sadetsky, Natalia Chaudhary, Nayan Lu, Michael W. Riely, Gregory J. Clin Cancer Res Clinical Trials: Immunotherapy PURPOSE: The utility of real-world data (RWD) for use as external controls in drug development is informed by studies that replicate trial control arms for different endpoints. The purpose of this study was to replicate control arms from four non–small cell lung cancer (NSCLC) randomized controlled trials (RCT) to analyze overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) using RWD. PATIENTS AND METHODS: This study used RWD from a nationwide de-identified database and a clinico-genomic database to replicate OS, PFS, and ORR endpoints in the chemotherapy control arms of four first-line NSCLC RCTs evaluating atezolizumab [IMpower150–wild-type (WT), IMpower130-WT, IMpower131, and IMpower132]. Additional objectives were to develop a definition of real-world PFS (rwPFS) and to evaluate the real-world response rate (rwRR) endpoint. RESULTS: Baseline demographic and clinical characteristics were balanced after application of propensity score weighting methods. For rwPFS and OS, RWD external controls were generally similar to their RCT control counterparts. Across all four trials, the hazard ratio (HR) point estimates comparing trial controls with external controls were closer to 1.0 for the PFS endpoint than for the OS endpoint. An exploratory assessment of rwRR in RWD revealed a slight but nonsignificant overestimation of RCT ORR, which was unconfounded by baseline characteristics. CONCLUSIONS: RWD can be used to reasonably replicate the OS and PFS of chemotherapy control arms of first-line NSCLC RCTs. Additional studies can provide greater insight into the utility of RWD in drug development. American Association for Cancer Research 2022-07-01 2022-05-05 /pmc/articles/PMC9355621/ /pubmed/35511917 http://dx.doi.org/10.1158/1078-0432.CCR-22-0471 Text en ©2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Clinical Trials: Immunotherapy Ton, Thanh G.N. Pal, Navdeep Trinh, Huong Mahrus, Sami Bretscher, Michael T. Machado, Robson J.M. Sadetsky, Natalia Chaudhary, Nayan Lu, Michael W. Riely, Gregory J. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data |
title | Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data |
title_full | Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data |
title_fullStr | Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data |
title_full_unstemmed | Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data |
title_short | Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data |
title_sort | replication of overall survival, progression-free survival, and overall response in chemotherapy arms of non–small cell lung cancer trials using real-world data |
topic | Clinical Trials: Immunotherapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355621/ https://www.ncbi.nlm.nih.gov/pubmed/35511917 http://dx.doi.org/10.1158/1078-0432.CCR-22-0471 |
work_keys_str_mv | AT tonthanhgn replicationofoverallsurvivalprogressionfreesurvivalandoverallresponseinchemotherapyarmsofnonsmallcelllungcancertrialsusingrealworlddata AT palnavdeep replicationofoverallsurvivalprogressionfreesurvivalandoverallresponseinchemotherapyarmsofnonsmallcelllungcancertrialsusingrealworlddata AT trinhhuong replicationofoverallsurvivalprogressionfreesurvivalandoverallresponseinchemotherapyarmsofnonsmallcelllungcancertrialsusingrealworlddata AT mahrussami replicationofoverallsurvivalprogressionfreesurvivalandoverallresponseinchemotherapyarmsofnonsmallcelllungcancertrialsusingrealworlddata AT bretschermichaelt replicationofoverallsurvivalprogressionfreesurvivalandoverallresponseinchemotherapyarmsofnonsmallcelllungcancertrialsusingrealworlddata AT machadorobsonjm replicationofoverallsurvivalprogressionfreesurvivalandoverallresponseinchemotherapyarmsofnonsmallcelllungcancertrialsusingrealworlddata AT sadetskynatalia replicationofoverallsurvivalprogressionfreesurvivalandoverallresponseinchemotherapyarmsofnonsmallcelllungcancertrialsusingrealworlddata AT chaudharynayan replicationofoverallsurvivalprogressionfreesurvivalandoverallresponseinchemotherapyarmsofnonsmallcelllungcancertrialsusingrealworlddata AT lumichaelw replicationofoverallsurvivalprogressionfreesurvivalandoverallresponseinchemotherapyarmsofnonsmallcelllungcancertrialsusingrealworlddata AT rielygregoryj replicationofoverallsurvivalprogressionfreesurvivalandoverallresponseinchemotherapyarmsofnonsmallcelllungcancertrialsusingrealworlddata |